<?xml version="1.0" encoding="UTF-8"?>
<p id="Par69">Eight deaths (7 in the BTH1677 arm; 1 in the Control arm) were reported in the treatment phase of within 30Â days of the last dose of study medication. Six of the 7 deaths in the BTH1677 arm were due to disease progression or complications of disease progression (e.g., pneumonia due to lung cancer, pneumothorax); the other death was due to intracranial hemorrhage that occurred subsequent to administration of anticoagulant for a blood clot in the lung. The 1 death in the Control arm was due to complications of disease progression (pneumonia due to lung cancer).</p>
